[{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2024","type":"Acquisition","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"||Epithelial cell adhesion molecule","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OcuMension Therapeutics \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"OcuMension Therapeutics \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"OcuMension Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Suspension","sponsorNew":"OcuMension Therapeutics \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"OcuMension Therapeutics \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Financing","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"OcuMension Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Implant","sponsorNew":"OcuMension Therapeutics \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"OcuMension Therapeutics \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"OcuMension Therapeutics \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"OcuMension Therapeutics \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"OcuMension Therapeutics \/ OcuMension Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"OcuMension Therapeutics \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Nicox SA"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"OcuMension Therapeutics \/ Nicox SA"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"OcuMension Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"OcuMension Therapeutics \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"OcuMension Therapeutics \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"OcuMension Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"OcuMension Therapeutics \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Beijing Children's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Beijing Children's Hospital","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Beijing Children's Hospital"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Nicox SA"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ OcuMension Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Licensing Agreement","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ OcuMension Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Ora, Inc | Statistics & Data Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"OT-101","moa":"TGF beta-2 messenger RNA (TGFB2 mRNA)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Ora, Inc | Statistics & Data Corporation","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Ora, Inc | Statistics & Data Corporation"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"OT202","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"SanBio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"Vandefitemcel","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"OcuMension Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"OcuMension Therapeutics \/ OcuMension Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"OcuMension Therapeutics \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Shandong Boan Biological Technology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OcuMension Therapeutics \/ Shandong Boan Biological Technology","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Shandong Boan Biological Technology"}]
Find Clinical Drug Pipeline Developments & Deals by OcuMension Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
